Aller au contenu principal
xMedica

NCT06628908ClinicalTrials.gov

Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy

A Phase 3, Randomized, Double-blind, Placebo- and Active-Controlled Study of the Efficacy and Safety of Suzetrigine in Subjects With Pain Associated With Diabetic Peripheral Neuropathy

En recrutementAccepte des participants actuellement, selon la fiche du registre.
Contacter cette étude

En bref

The purpose of this study is to evaluate the efficacy, safety, and tolerability of Suzetrigine (SUZ) in participants with pain associated with diabetic peripheral neuropathy (DPN).

Phase 31 100 participants recherchés76 sites1 pays

Catégories

Enregistré dans 1 registre

Une même étude peut être enregistrée dans plusieurs registres. Nous l'affichons une seule fois et renvoyons vers chaque fiche que nous détenons.

Les informations de l'essai sont affichées telles que publiées par le registre, dans leur langue d'origine.

Cette étude vous intéresse ?

Se connecter ou créez un compte pour manifester votre intérêt et suivre cette étude.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Not stated: Registered after enrolment began (about 7 days after the recorded start)First posted 2024-10-08; recorded start 2024-10-01
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Present: Uses blinding (masking)A masking level is recorded in the record
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 92 other studies in this databaseCounted from the lead sponsor named in the record (Vertex Pharmaceuticals Incorporated)
  • Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourDEFINITIVE

A definitive-grade design for a phase 3 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding20/20

    Quadruple-blind

  • Control arm15/15

    Active-comparator control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre8/8

    Multi-centre: 76 sites

  • Data monitoring committee0/7

    Data monitoring committee not stated in the record

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleLARGE

A large study: 1,100 participants (target), run at 76 sites.

How this score is built
  • Enrolment30/40

    1,100 participants (target)

  • Site count22/25

    76 sites

  • Country count0/15

    Single country

  • Planned duration8/10

    Planned over about 32 months

  • Sponsor scale7/10

    Vertex Pharmaceuticals Incorporated has led 90 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Résumé

The purpose of this study is to evaluate the efficacy, safety, and tolerability of Suzetrigine (SUZ) in participants with pain associated with diabetic peripheral neuropathy (DPN).

Affections

  • Diabetic Peripheral Neuropathic Pain

Éligibilité

Éligibilité
SexeTous
Âges18 Years80 Years
Volontaires sainsNon

Éligibilité telle qu'elle figure dans le registre

Key Inclusion Criteria: * Body weight greater than or equal to (≥) 45 kilogram (kg) * Body mass index (BMI) ≥18.0 to less than (\<) 40.0 kilogram per meter square (kg/m\^2) * Diagnosis of diabetes mellitus type 1 or type 2 by glycosylated hemoglobin A1c (HbA1c) ≤9% and the presence of bilateral pain in lower extremities due to DPN * Weekly average of daily NPRS score ≥4 and less than or equal to (≤) 9 with limited variation in the 7-day Baseline Period Key Exclusion Criteria: * More than 3 missing daily NPRS scores during the 7-day Baseline Period * Any sensory abnormality (excluding DPN) as pre-specified in the protocol Other protocol defined Inclusion/Exclusion criteria may apply.

Éligibilité en énoncés simples

Les critères de cette fiche n'ont pas encore été décomposés en énoncés distincts. Le texte du registre ci-dessus est complet et fait foi.

Conception de l'étude

Conception de l'étude
Type d'étudeInterventionnelle
PhasePhase 3
RépartitionRandomisée
Modèle d'interventionPARALLEL
Objectif principalTREATMENT
InsuQUADRUPLE (4)
Recrutement1 100 participants recherchés

Promoteur et collaborateurs

  • Vertex Pharmaceuticals Incorporated Promoteur

Groupes et interventions

  • Suzetrigine (SUZ)EXPERIMENTAL

    Participants will be randomized to receive SUZ.

  • PregabalinACTIVE_COMPARATOR

    Participants will be randomized to receive Pregabalin.

  • PlaceboPLACEBO_COMPARATOR

    Participants will be randomized to receive placebo matched to SUZ and Pregabalin.

Interventions

  • Médicament Placebo (matched to Pregabalin)

    Placebo matched to Pregabalin for oral administration.

  • Médicament Placebo (matched to SUZ)

    Placebo matched to SUZ for oral administration.

  • Médicament Pregabalin

    Capsules for oral administration.

  • Médicament Suzetrigine

    Tablets for oral administration.

Critères de jugement

  1. Critère de jugement principal

    Change From Baseline in the Weekly Average of Daily Pain Intensity on the Numeric Pain Rating Scale (NPRS) at Week 12 Compared to Placebo

    Délai From Baseline up to Week 12

  2. Critère de jugement secondaire

    Change From Baseline in the Medical Outcomes Study 36-item Short-form Health Status (SF 36v2) Physical Component Summary (PCS) Score at Week 12 Compared to Placebo (pooled with data from Study VX24-548-111)

    Délai From Baseline up to Week 12

  3. Critère de jugement secondaire

    Change From Baseline in the Weekly Average of Daily Pain Intensity on the NPRS at Week 12 Compared to Pregabalin

    Délai From Baseline up to Week 12

Dates

Dates
Date de début1 octobre 2024 (réelle)
Achèvement principal31 mai 2027 (estimée)
Achèvement31 mai 2027 (estimée)
Première publication8 octobre 2024 (réelle)
Dernière mise à jour15 juin 2026
Résultats publiésNon précisé dans la fiche du registre
Statut vérifié pour la dernière foisjuin 2026

Réelle signifie que l'événement a eu lieu. Estimée signifie que le promoteur s'y attend. Les deux ont un sens différent.

Lieux

59 sites sont en recrutement

United States

United States
ÉtablissementVilleÉtat ou régionStatut
Albany Medical CollegeAlbanyNew YorkTerminé
Velocity Clinical Research - AlbuquerqueAlbuquerqueNew MexicoEn recrutement
Synexus Clinical Research- AndersonAndersonSouth CarolinaTerminé
Pinnacle Research Group, LLCAnnistonAlabamaEn recrutement
Velocity Clinical Research - Baton RougeBaton RougeLouisianaEn recrutement
Velocity Clinical Research - ClevelandBeachwoodOhioEn recrutement
Northwest Clinical Research Center (NWCRC)BellevueWashingtonEn recrutement
Synexus Clinical Research - BirminghamBirminghamAlabamaTerminé
Mass General Brigham - Brigham and Women's Hospital - Main CampusBostonMassachusettsEn recrutement
Swift Clinical OpCo, IncBrooklynNew YorkEn recrutement
Clinical Trials of South Carolina - Berkeley - CharlestonCharlestonSouth CarolinaEn recrutement
M3 Wake Research - CharlestonCharlestonSouth CarolinaEn recrutement
Feinberg School of Medicine - AnesthesiologyChicagoIllinoisEn recrutement
Synexus Clinical Research - CincinnatiCincinnatiOhioTerminé
Tandem Clinical Research- CovingtonCovingtonLouisianaEn recrutement
Synexus Clinical Research - Dallas (DFW) (DRS)DallasTexasTerminé
Zenos Clinical ResearchDallasTexasEn recrutement
AMR Daphne, ALDaphneAlabamaTerminé
META Medical Research InstituteDaytonOhioEn recrutement
Accel Research - DelandDeLandFloridaEn recrutement
Accel Research - DecaturDecaturGeorgiaEn recrutement
AMR-MiamiDoralFloridaEn recrutement
Velocity Clinical Research - ProvidenceEast GreenwichRhode IslandEn recrutement
Velocity Clinical Research - SyracuseEast SyracuseNew YorkEn recrutement
Velocity Clinical Research - DenverEnglewoodColoradoEn recrutement
Synexus Clinical Research - EvansvilleEvansvilleIndianaTerminé
Healthcare Research Network - Flossmoor ILFlossmoorIllinoisEn recrutement
AMR Fort Myers (The Clinical Study Center)Fort MyersFloridaEn recrutement
Neuro-Pain Medical CenterFresnoCaliforniaEn recrutement
Velocity Clinical Research - Grants PassGrants PassOregonTerminé
Velocity Clinical Research - Hallandale BeachHallandaleFloridaEn recrutement
Healthcare Research Network - Hazelwood MOHazelwoodMissouriEn recrutement
CNS Healthcare - JacksonvilleJacksonvilleFloridaEn recrutement
AMR Kansas CityKansas CityMissouriEn recrutement
Accel Research - St. Petersburg-LargoLargoFloridaEn recrutement
Synexus Clinical Research - Las VegasLas VegasNevadaTerminé
AMR LexingtonLexingtonKentuckyEn recrutement
Long Beach Research InstituteLong BeachCaliforniaEn recrutement
Angel City Research, IncLos AngelesCaliforniaEn recrutement
Accel Research - MaitlandMaitlandFloridaTerminé
HRI - Hassman Research InstituteMarltonNew JerseyTerminé
Velocity Clinical Research - MedfordMedfordOregonEn recrutement
Suburban Research Associates - MediaMediaPennsylvaniaEn recrutement
Velocity Clinical Research - BoiseMeridianIdahoEn recrutement
Suncoast Research Associates - MiamiMiamiFloridaEn recrutement
3Sync Research - Miami LakesMiami LakesFloridaEn recrutement
West Clinical ResearchMorehead CityNorth CarolinaEn recrutement
AMR Nashville, TNNashvilleTennesseeTerminé
Suncoast Clinical Research - New Port RicheyNew Port RicheyFloridaEn recrutement
Columbia Presbyterian - The Neurological Institute of New YorkNew YorkNew YorkEn recrutement

26 sites supplémentaires sont indiqués dans la fiche du registre.

Documents de l'étude

Aucun document n'est lié dans cette fiche du registre.

Évolution au fil du temps

Aucun changement n'a été enregistré depuis que nous avons intégré cette fiche pour la première fois.

Un changement est enregistré chaque fois que le promoteur met à jour la fiche du registre. Le statut, les dates, le recrutement et les sites apparaissent ici au fur et à mesure de leur évolution.